Eastern Sunshine Herbal Escitalopram Oxalate Tablets Entered the Administrative Approval Stage

Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for marketing.

Escitalopram is the single-S-enantiomer of citalopram, a bicyclic hydrogenated phthalide derivative, and is clinically used to treat depression, panic disorder with or without agoraphobia.

According to data from Meinenet, the total sales of escitalopram oxalate tablets in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 exceeded 20 100 million yuan, the growth rate has declined in the first half of 2020.

Consistency evaluation and application status of escitalopram oxalate tablets (including new classification for production)

Source: Meinenet MED2.

At present, 5 companies have submitted supplementary applications for the consistency evaluation of escitalopram oxalate tablets.

From 2021 to the present, Dongyang Pharmaceutical has been approved for marketing

Source: Meinenet MED2.

According to data from Minai.

New antidepressant drug being developed by Dongyang Sun Pharmaceutical

Source: Meinenet MED2.

In terms of new antidepressant drugs, the domestic class 1 new drug HEC113995PA·H2O tablets are in phase I clinical trials, and the 2.

Source: Minet database

Note: The statistics are as of March 25.